title: In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells.
abstract: The response of pancreatic cancer to treatments remains unsatisfactory, highlighting the need for more effective therapeutic regimens. Sorafenib, an orally available multikinase inhibitor, is active against different tumors, including pancreatic cancer. We studied the antitumor efficacy of sorafenib in combination with different antitumor drugs currently used in clinical practice in in vitro and in vivo experimental models of human pancreatic cancer. The cytotoxic effect of sorafenib and conventional antitumor drug combinations was evaluated in vitro in human pancreatic cancer cell lines and the efficacy of the most active combination was tested on tumor-bearing mice. Flow cytometric, Western blot and immunohistochemistry analyses were performed to investigate the mechanisms involved in the activity of single drugs and in their interaction when used in combination. Sorafenib showed a strong sequence-dependent synergistic interaction in vitro with docetaxel, which was highly dependent on the drug sequence employed. In vivo, human pancreatic cancer-xenografted mice treated with docetaxel followed by sorafenib reduced and delayed tumor growth, with complete tumor regression observed in half of the mice. This marked antitumor effect resulted in an overall increase in mouse survival of about 70% and in a complete cure in 3 of the 8 treated mice. The strong activity was also accompanied by marked apoptosis induction, inhibition of tumor angiogenesis and downregulation of ERK signalling. Our results show that the docetaxel and sorafenib combination exerts high therapeutic efficacy in experimental models of human pancreatic cancer, indicating a promising antitumor strategy for clinical use.
authors.affiliation: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Ulivi
authors.forename: C
authors.initials: C
authors.lastname: Arienti
authors.forename: W
authors.initials: W
authors.lastname: Zoli
authors.forename: M
authors.initials: M
authors.lastname: Scarsella
authors.forename: S
authors.initials: S
authors.lastname: Carloni
authors.forename: F
authors.initials: F
authors.lastname: Fabbri
authors.forename: A
authors.initials: A
authors.lastname: Tesei
authors.forename: E
authors.initials: E
authors.lastname: Chiadini
authors.forename: A
authors.initials: A
authors.lastname: Orlandi
authors.forename: D
authors.initials: D
authors.lastname: Passeri
authors.forename: G
authors.initials: G
authors.lastname: Zupi
authors.forename: C
authors.initials: C
authors.lastname: Milandri
authors.forename: R
authors.initials: R
authors.lastname: Silvestrini
authors.forename: D
authors.initials: D
authors.lastname: Amadori
authors.forename: C
authors.initials: C
authors.lastname: Leonetti
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D001557:Benzenesulfonates / Q000008:administration & dosage; D000077143:Docetaxel; D004347:Drug Interactions; D006801:Humans; D009536:Niacinamide / Q000031:analogs & derivatives; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010671:Phenylurea Compounds; D011725:Pyridines / Q000008:administration & dosage; D000077157:Sorafenib; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D043823:Taxoids; D000077143:Docetaxel; D009536:Niacinamide; D000077157:Sorafenib